This theme involves the development and clinical trialling of novel therapies for cancer based on two principles
-
using the specificity of the cellular immune system to recognise and kill tumour cells selectively
-
using vector-mediated delivery to tumour cells of genes that sensitise the cells to chemotherapeutic pro-drugs.
For both approaches, viruses provide an important entrée. Thus virus-associated cancers are key targets of choice for the development of immune therapies, while other viruses provide the key vectors for tumour-specific gene delivery.
This work complements and extends that described in the Viral Oncology Theme.